347 related articles for article (PubMed ID: 26997129)
1. Cancer stem cell molecular reprogramming of the Warburg effect in glioblastomas: a new target gleaned from an old concept.
Yuen CA; Asuthkar S; Guda MR; Tsung AJ; Velpula KK
CNS Oncol; 2016; 5(2):101-8. PubMed ID: 26997129
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.
Mahase S; Rattenni RN; Wesseling P; Leenders W; Baldotto C; Jain R; Zagzag D
Am J Pathol; 2017 May; 187(5):940-953. PubMed ID: 28284719
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.
Sanzey M; Abdul Rahim SA; Oudin A; Dirkse A; Kaoma T; Vallar L; Herold-Mende C; Bjerkvig R; Golebiewska A; Niclou SP
PLoS One; 2015; 10(5):e0123544. PubMed ID: 25932951
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling Warburg effect and stemness in CD133
Koka P; Mundre RS; Rangarajan R; Chandramohan Y; Subramanian RK; Dhanasekaran A
Mol Biol Rep; 2018 Dec; 45(6):1653-1662. PubMed ID: 30128626
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.
Velpula KK; Bhasin A; Asuthkar S; Tsung AJ
Cancer Res; 2013 Dec; 73(24):7277-89. PubMed ID: 24148623
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
7. Suppression of lactate dehydrogenase A compromises tumor progression by downregulation of the Warburg effect in glioblastoma.
Li J; Zhu S; Tong J; Hao H; Yang J; Liu Z; Wang Y
Neuroreport; 2016 Jan; 27(2):110-5. PubMed ID: 26694942
[TBL] [Abstract][Full Text] [Related]
8. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
D'Alessio A; Proietti G; Lama G; Biamonte F; Lauriola L; Moscato U; Vescovi A; Mangiola A; Angelucci C; Sica G
Oncotarget; 2016 Nov; 7(48):78541-78556. PubMed ID: 27705944
[TBL] [Abstract][Full Text] [Related]
9. Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma.
Eriksson JA; Wanka C; Burger MC; Urban H; Hartel I; von Renesse J; Harter PN; Mittelbronn M; Steinbach JP; Rieger J
J Neurochem; 2018 Feb; 144(4):421-430. PubMed ID: 29178334
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
11. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
12. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.
Agnihotri S; Zadeh G
Neuro Oncol; 2016 Feb; 18(2):160-72. PubMed ID: 26180081
[TBL] [Abstract][Full Text] [Related]
14. Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.
Shibao S; Minami N; Koike N; Fukui N; Yoshida K; Saya H; Sampetrean O
Neuro Oncol; 2018 Feb; 20(3):343-354. PubMed ID: 29016888
[TBL] [Abstract][Full Text] [Related]
15. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
16. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
[TBL] [Abstract][Full Text] [Related]
17. The Anti-Warburg Effect Elicited by the cAMP-PGC1α Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes.
Xing F; Luan Y; Cai J; Wu S; Mai J; Gu J; Zhang H; Li K; Lin Y; Xiao X; Liang J; Li Y; Chen W; Tan Y; Sheng L; Lu B; Lu W; Gao M; Qiu P; Su X; Yin W; Hu J; Chen Z; Sai K; Wang J; Chen F; Chen Y; Zhu S; Liu D; Cheng S; Xie Z; Zhu W; Yan G
Cell Rep; 2017 Jan; 18(2):468-481. PubMed ID: 28076790
[TBL] [Abstract][Full Text] [Related]
18. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A.
Abdul Rahim SA; Dirkse A; Oudin A; Schuster A; Bohler J; Barthelemy V; Muller A; Vallar L; Janji B; Golebiewska A; Niclou SP
Br J Cancer; 2017 Sep; 117(6):813-825. PubMed ID: 28797031
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas.
Miranda-Gonçalves V; Granja S; Martinho O; Honavar M; Pojo M; Costa BM; Pires MM; Pinheiro C; Cordeiro M; Bebiano G; Costa P; Reis RM; Baltazar F
Oncotarget; 2016 Jul; 7(29):46335-46353. PubMed ID: 27331625
[TBL] [Abstract][Full Text] [Related]
20. Involvement of collagen XVII in pluripotency gene expression and metabolic reprogramming of lung cancer stem cells.
Hsu HS; Liu CC; Lin JH; Hsu TW; Hsu JW; Li AF; Hung SC
J Biomed Sci; 2020 Jan; 27(1):5. PubMed ID: 31928533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
